Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid

Trial Profile

Prevention of symptomatic skeletal events in patients with genitourinary (GU) tumours and bone metastases treated with denosumab or zoledronic acid

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2014

At a glance

  • Drugs Denosumab (Primary) ; Zoledronic acid
  • Indications Bone metastases; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 12 May 2014 New trial record
    • 11 Apr 2014 Results presented at the 29th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top